Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels
- PMID: 17981115
- DOI: 10.1016/j.cell.2007.08.038
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels
Abstract
Novel antiangiogenic strategies with complementary mechanisms are needed to maximize efficacy and minimize resistance to current angiogenesis inhibitors. We explored the therapeutic potential and mechanisms of alphaPlGF, an antibody against placental growth factor (PlGF), a VEGF homolog, which regulates the angiogenic switch in disease, but not in health. alphaPlGF inhibited growth and metastasis of various tumors, including those resistant to VEGF(R) inhibitors (VEGF(R)Is), and enhanced the efficacy of chemotherapy and VEGF(R)Is. alphaPlGF inhibited angiogenesis, lymphangiogenesis, and tumor cell motility. Distinct from VEGF(R)Is, alphaPlGF prevented infiltration of angiogenic macrophages and severe tumor hypoxia, and thus, did not switch on the angiogenic rescue program responsible for resistance to VEGF(R)Is. Moreover, it did not cause or enhance VEGF(R)I-related side effects. The efficacy and safety of alphaPlGF, its pleiotropic and complementary mechanism to VEGF(R)Is, and the negligible induction of an angiogenic rescue program suggest that alphaPlGF may constitute a novel approach for cancer treatment.
Comment in
-
alphaPlGF: a new kid on the antiangiogenesis block.Cell. 2007 Nov 2;131(3):443-5. doi: 10.1016/j.cell.2007.10.023. Cell. 2007. PMID: 17981110
Similar articles
-
alphaPlGF: a new kid on the antiangiogenesis block.Cell. 2007 Nov 2;131(3):443-5. doi: 10.1016/j.cell.2007.10.023. Cell. 2007. PMID: 17981110
-
PlGF blockade does not inhibit angiogenesis during primary tumor growth.Cell. 2010 Apr 2;141(1):166-77. doi: 10.1016/j.cell.2010.01.033. Cell. 2010. PMID: 20371352
-
Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation.Cancer Res. 2010 Aug 15;70(16):6537-47. doi: 10.1158/0008-5472.CAN-09-4092. Epub 2010 Aug 3. Cancer Res. 2010. PMID: 20682798
-
Tumor angiogenesis and anti-angiogenic therapies.Hum Antibodies. 2013;22(1-2):15-9. doi: 10.3233/HAB-130267. Hum Antibodies. 2013. PMID: 24284305 Review.
-
Tumor angiogenesis and anti-angiogenic therapy.Keio J Med. 2012;61(2):47-56. doi: 10.2302/kjm.61.47. Keio J Med. 2012. PMID: 22760023 Review.
Cited by
-
Melatonin downregulates angiogenesis and lymphangiogenesis by regulating tumor-associated macrophages via NLRP3 inflammasomes in lung adenocarcinoma.Aging (Albany NY). 2024 Sep 3;16(17):12225-12238. doi: 10.18632/aging.206057. Epub 2024 Sep 3. Aging (Albany NY). 2024. PMID: 39230586 Free PMC article.
-
PD-L1-directed PlGF/VEGF blockade synergizes with chemotherapy by targeting CD141+ cancer-associated fibroblasts in pancreatic cancer.Nat Commun. 2022 Oct 22;13(1):6292. doi: 10.1038/s41467-022-33991-6. Nat Commun. 2022. PMID: 36272973 Free PMC article.
-
Functionalization of Osteoplastic Material with Human Placental Growth Factor and Assessment of Biocompatibility of the Resulting Material In Vitro.Pharmaceutics. 2024 Jan 8;16(1):85. doi: 10.3390/pharmaceutics16010085. Pharmaceutics. 2024. PMID: 38258096 Free PMC article.
-
Serum protein N-glycan alterations of diethylnitrosamine-induced hepatocellular carcinoma mice and their evolution after inhibition of the placental growth factor.Mol Cell Biochem. 2013 Jan;372(1-2):199-210. doi: 10.1007/s11010-012-1461-1. Epub 2012 Sep 24. Mol Cell Biochem. 2013. PMID: 23001868
-
Comprehensive analysis of potential cellular communication networks in advanced osteosarcoma using single-cell RNA sequencing data.Front Genet. 2022 Oct 11;13:1013737. doi: 10.3389/fgene.2022.1013737. eCollection 2022. Front Genet. 2022. PMID: 36303551 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
